Trial Profile
Everolimus in Combination With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 16 Nov 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
- 16 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.